**Abstract**

**Background and Objectives:** Atypical antipsychotics provide better control of the negative and affective symptoms of schizophrenia when compared with conventional neuroleptics. Nevertheless, their heightened ability to improve cognitive dysfunction remains a matter of debate. This study aimed to examine the changes in cognition associated with long-term antipsychotic treatment and to evaluate the effect of the type of antipsychotic (conventional *versus* novel antipsychotic drugs) on cognitive performance over time.

**Methods:** In this naturalistic study, we used a comprehensive neuropsychological battery of tests to assess a sample of schizophrenia patients taking either conventional (*n* = 21) or novel antipsychotics (*n* = 32) at baseline and at two years after.

These tests were used to measure seven neurocognitive domains, (Executive Functions, Working Memory, Verbal Memory, Visual Memory, Visual-Motor Processing, Semantic Verbal Fluency and Motor Speed).

The clinical evaluation of each patient was rated according to the Positive and Negative Symptom Scale and to the Hamilton Rating Scale for Depression. Premorbid adjustment was assessed using the Phillips Adjustment Scale.

**Results:** Continuous antipsychotic treatment regardless of class was associated with improvement on verbal fluency, executive functions, and visual and verbal memory. The variable "type of antipsychotic" did not predict the improvement of performance in any of the neuropsychological tests, as assessed using regression analyses. However, intake of anticholinergic drugs seems to predict cognitive changes significantly.

**Conclusions:** In the absence of other reasons to change ongoing treatment, which include negative or affective symptoms or lack of compliance with the regimen, the switch from typical APD at low or moderate doses to atypical APDs is not justified if based solely on the expectation of a more favorable cognitive outcome.
